Low dose computed tomography
Diagnostic TestLow dose computed tomography for lung cancer screening
NCT Number: NCT07383454
Study design: prospective, single arm.
Objectives: survey lung cancer detection rate of low-dose computed tomography (LDCT) screening in individuals who had never smoked.
Participants will undergo questionnaires, and collecting specimens including blood, urine, and medical informations including results of pulmonary function tests, and LDCT screening upon inclusion. The participants will be followed up according to current standards of clinical practice.
Trial opening soon.
Get Notified40 year–80 year
All sexes
Interventional
Not applicable
Lung cancer remains the leading cause of cancer-related mortality worldwide, with a particularly high incidence and mortality rate in Taiwan. Notably, over half of lung cancer cases in Taiwan occur among individuals who have never smoked, a pattern distinct from Western populations. In response to this unique epidemiological profile, this project aims to promote community-based lung cancer screening among never-smokers and to validate the FORMOSA lung cancer risk prediction model, which integrates demographic, environmental, genetic, and clinical factors.
This prospective, single-arm, open-label study will recruit approximately 2,500 participants aged 40 to 80 years with no history of smoking, through hospital and community outreach. Eligible participants will provide informed consent and undergo comprehensive assessments, including questionnaires on lifestyle and environmental exposures, low-dose computed tomography (LDCT), chest X-ray, pulmonary function tests, and collection of blood and urine samples. LDCT results will be interpreted according to the modified ACR Lung-RADS v1.1 criteria. Biological specimens will be used for biomarker, heavy metal, genetic, and proteomic analyses. Participants with abnormal findings will be followed according to standard clinical protocols, and tissue samples from invasive procedures will be retained for further molecular studies.
The primary outcomes include the lung cancer detection rate among never-smoked participants and the validation metrics (sensitivity, specificity, positive and negative predictive values) of the FORMOSA lung cancer risk prediction model. Statistical analyses will employ descriptive statistics, Kaplan-Meier survival analysis, log-rank tests, Cox proportional hazards models, and group comparisons using ANOVA, Kruskal-Wallis, chi-square, Fisher's exact tests, and logistic-regression. Preliminary data suggest that the FORMOSA model can identify high-risk individuals with a lung cancer detection rate of 2.8-3.3%, significantly higher than the general population rate of 0.78%.
This project is expected to enhance early detection of lung cancer in never-smokers, improve public awareness, and establish a robust epidemiological database for Taiwan. The validation of the FORMOSA model will provide a scientific basis for refining screening strategies and inform future public health policies targeting high-risk, non-smoking populations. The study is conducted with strict adherence to ethical standards, ensuring participant rights and data security. Funding is provided by the Ministry of Health and Welfare's "Healthy Taiwan Deep Cultivation Plan." In summary, this research addresses a critical gap in lung cancer prevention by focusing on never-smokers, leveraging a comprehensive risk prediction model, and implementing a community-based screening approach. The anticipated outcomes will contribute significantly to reducing late-stage lung cancer diagnoses and mortality, and serve as a reference for future health policy development in Taiwan and similar populations.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Low dose computed tomography for lung cancer screening
Time frame: 8 years of follow-up
The rate of lung cancer diagnosis during follow up periord.
Time frame: 8 years
Assess the sensitivity, specificity, positive predicting value, negative predicting value, and ROC analysis of FORMOSA Lung Cancer Risk Prediction Model
Contact information is provided by the study sponsor or research team.
Gee-Chen Chang, MD, PhD.
CONTACT
886-4-24739595 ext. 34414
Lung-Ying Huang, Mrs.
CONTACT
886-4-24739595 ext. 34414
Chung Shan Medical University
Other
Lung Cancer Screening in Population Who Had Never Smoked and the Validation of Lung Cancer Risk Prediction Model
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07510724
Bronchial Neoplasms, Carcinoma, Bronchogenic
Sankt Pölten, Lower Austria, Austria
View Trial DetailsNCT07581379
Bronchial Neoplasms, Carcinoma, Bronchogenic
Gainesville, Florida, United States
View Trial DetailsNCT07384897
Bronchial Neoplasms, Carcinoma, Bronchogenic
Brussels, Belgium
View Trial DetailsNCT07325864
Bronchial Neoplasms, Carcinoma, Bronchogenic
Milan, Italy
View Trial Details